Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to see if an experimental drug, called MM-093, is safe
and effective in the treatment of rheumatoid arthritis. MM-093 is a genetically engineered
version of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have
very small amounts of AFP in their bloodstream. However, during pregnancy, AFP levels in both
the mother and the fetus are much higher than normal. It has been observed that women with RA
(Rheumatoid Arthritis) have fewer symptoms during pregnancy, particularly during the third
trimester. At this time, the levels of AFP in the blood of the mother and fetus are the
highest. This observation led researchers to begin examining AFP as a possible treatment for
RA.